Clinician's Roundtable

Based on a randomized study, children with higher baseline thresholds of peanut reactivity achieved markedly higher rates of sustained unresponsiveness after oral immunotherapy compared with untreated peers. Learn more about this study and its clinical implications with Dr. Scott H. Sicherer. Not only is he a Professor of Pediatrics and the Director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, but he also spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

While anti-VEGF therapy can deliver vision gains with consistent, frequent injections in clinical trials, it may be challenging to sustain this in real-world practice.1 Ocular gene therapy could be a potential option for patients with neovascular age-related macular degeneration if approved. With this approach, transgenes are delivered to the eye by adeno-associated viruses (AAVs).2-4 Learn more with Drs. Courtney Crawford and Raj Maturi, who shared their perspectives on investigational gene therapy, patient conversations, and surgical considerations at the 2025 American Academy of Ophthalmology annual meeting in Orlando, Florida.

Dr. Crawford is a board-certified retina specialist and founder of Star Retina in Burleson, Texas. He previously served for 10 years as a physician in the U.S. Army, where he attained the rank of Lieutenant Colonel. Dr. Maturi is a board-certified retina specialist at the Midwest Eye Institute and founder of Retina Partners Midwest in Carmel, Indiana, where he focuses on macular, retina, and vitreous care.

References:

1. Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing visual outcomes in patients with neovascular age-related macular degeneration: the potential value of sustained anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2023;54:654–659.
2. Petrich J, Marchese D, Jenkins C, Storey M, Blind J. …

From early metabolic risks to advanced liver disease, the progressive burden associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) requires timely, informed care. Hear from Dr. Peter Buch as he shares practical guidance on intervention strategies and provides a closer look at current and emerging treatments shaping patient outcomes. Dr. Buch is a board-certified clinical gastroenterologist and Associate Professor at the Frank H. Netter, MD School of Medicine at Quinnipiac University.

Fracture patients receiving anticoagulation therapy face increased risks for bleeding and complications, particularly when urgent surgical intervention is needed. That’s why understanding how fracture type, injury severity, and anticoagulant choice influence timing and management decisions is critical to optimizing outcomes. Joining Dr. Alexandria May to discuss bleeding risk assessment, anticoagulation reversal strategies, and the importance of coordinated, protocol-driven care for fracture patients on anticoagulation is Dr. Clay Spitler. He’s an orthopedic trauma surgeon and serves as Vice Chair of Clinical Affairs for the Department of Orthopedic Surgery at the University of Alabama at Birmingham.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing liver health concern that's closely linked to obesity and other cardiometabolic risk factors, yet it remains underrecognized in clinical practice. That's why Dr. Peter Buch joins us to discuss how emerging perspectives are changing the way we think about metabolic-related liver disease. Dr. Buch is a board-certified clinical gastroenterologist and Associate Professor at the Frank H. Netter, MD School of Medicine at Quinnipiac University in Connecticut.

With obesity rates rising to unprecedented levels, clinicians face critical challenges in managing associated complications. Hear from Dr. Sujith Cherian as he explores obesity’s systemic impact, from cardiovascular and infectious risks to medication dosing and hospital care complexities. Dr. Cherian is an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School. He also serves as the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston.

Obesity introduces distinct changes to respiratory physiology that ripple across care settings—from subtle outpatient symptoms to complex ventilatory challenges in the ICU and heightened perioperative risks. Dr. Sujith Cherian explains real-world scenarios and physiologic insights to show how excess weight influences not just lung mechanics, but length of stay, postoperative recovery, and cardiopulmonary complications. Dr. Cherian is an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School. He also serves as the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston.

A new preclinical study investigated whether Roseburia hominis, a gut microbe often depleted in individuals with obesity, could play a direct role in regulating metabolism. Learn more as Dr. Hallie Blevins explores these findings and their potential implications for future treatment of obesity and related metabolic disorders in this AudioAbstract.

What does it really mean to humanize medicine? In this candid conversation, Ryan Quigley and Dr. Michael Greenberg explore how clinicians can revive empathy, trust, and emotional connection in patient care, from intentional language shifts to brief yet meaningful moments of authentic connection. Dr. Greenberg is a dermatologist at the Illinois Dermatology Institute.

Timely surgical intervention is critical for reducing mortality and complications in high-risk hip fracture patients. However, anticoagulation therapy often presents barriers to prompt care, requiring careful coordination and clinical judgment. Joining Dr. Steve Jackson to discuss anticoagulant reversal strategies and multidisciplinary approaches for managing high-risk fracture patients are Drs. Anna Miller and Michael Weaver. Dr. Miller is a Professor of Orthopedics and the Chair of the Department of Orthopedics at Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth in Lebanon, New Hampshire. Dr. Weaver is an Associate Professor of Orthopedic Surgery at Harvard Medical School, as well as the Chief of Orthopedic Trauma and Distinguished Chair in Orthopedic Surgery at Brigham and Women's Hospital in Boston.